Equity Profile

LLY

Eli Lilly and Company

Health CarePharmaceuticals$1.1T

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:45 AM EDT

Eli Lilly Beats on EPS, Stock Up 9.8%

Metric	Actual	Expected	Surprise
EPS	$8.55	$6.84	+21.07%
Revenue	N/A	$17.8B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Eli Lilly Beats on EPS, Stock Up 9.8%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$8.55	$6.84	+21.07%
Revenue	N/A	$17.8B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Eli Lilly's strong earnings per share of $8.55 significantly exceeded expectations, contributing to a 9.8% rise in stock price. The positive surprise in EPS indicates robust performance, although revenue figures were not disclosed. Investors may view this as a sign of the company's strong operational efficiency and potential growth.

Company Snapshot

Eli Lilly and Company (LLY) is a leading pharmaceutical company that develops and manufactures medications for various health conditions, including diabetes and cancer. With a market cap of $764 billion, it plays a significant role in the healthcare sector, focusing on innovative treatments that address unmet medical needs.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$6.84

Revenue

Total revenue reflects the company's sales performance and growth potential, which is crucial for understanding market demand for its products.

$17.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

In the last quarter, Eli Lilly reported an EPS of $7.54, exceeding estimates by 7.88%, which positively impacted the stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall sales performance.

Management Promises & Guidance

Focus on expanding its diabetes and cancer treatment portfolios.
Commitment to maintaining strong research and development efforts.
Plans to enhance global market access for its key products.

Expectations

Wall Street Expectations

Analysts expect Eli Lilly to report strong earnings driven by its innovative drug portfolio, with a consensus EPS of $6.84. However, there are concerns about potential pricing pressures and competition in the pharmaceutical market.

Bull Case

If Eli Lilly beats EPS expectations and shows robust revenue growth, it could signal strong demand for its products, leading to a positive stock reaction.

Bear Case

If the company misses EPS estimates or provides weak guidance, it could raise concerns about its growth trajectory and lead to a negative market response.

Key Metrics to Watch

EPS

$6.84

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$17.8B

Total revenue reflects the company's sales performance and growth potential, which is crucial for understanding market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Eli Lilly's EPS exceed the consensus estimate of $6.84?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What guidance will management provide for future revenue growth?

Management's outlook on revenue growth will be critical for assessing the company's ability to sustain its momentum.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Eli Lilly's recent product launches, which could drive higher-than-expected sales.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

Options are pricing a 6.42% move, but the stock has historically moved more than that, suggesting potential for a larger reaction.

Key Risk

If the company reports strong sales growth in its key therapeutic areas, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

Investors are closely watching how the company balances growth with potential pricing pressures in the pharmaceutical market.

Bull Confirmed If

Eli Lilly must report an EPS above $7.00 and provide strong revenue guidance to confirm the bull case.

Bear Confirmed If

An EPS below $6.50 or weak revenue guidance would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.42%

Historical Avg

±8.6%

Pricing cheap

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±6.4% while LLY has averaged ±8.6% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

20.6%

Calls (2.0M)P/C Ratio: 0.86Puts (1.3M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests a potential stock increase of around +3.13%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around -8.97%, raising concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·5 sells

Members

House + Senate

Est. Notional

$22,008.00–$155,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of diabetes and cancer drugs.
2Any commentary on pricing strategies and market competition.
3Insights into research and development progress for new treatments.
4Management's outlook on global market expansion efforts.
5Details on cost management and operational efficiencies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

VZReported

Verizon Communications Inc.

Congress activity

RecapView

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$6.84

Revenue

Total revenue reflects the company's sales performance and growth potential, which is crucial for understanding market demand for its products.

$17.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

Management Promises & Guidance

Focus on expanding its diabetes and cancer treatment portfolios.
Commitment to maintaining strong research and development efforts.
Plans to enhance global market access for its key products.

Expectations

Wall Street Expectations

Bull Case

If Eli Lilly beats EPS expectations and shows robust revenue growth, it could signal strong demand for its products, leading to a positive stock reaction.

Bear Case

If the company misses EPS estimates or provides weak guidance, it could raise concerns about its growth trajectory and lead to a negative market response.

Key Metrics to Watch

EPS

$6.84

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$17.8B

Total revenue reflects the company's sales performance and growth potential, which is crucial for understanding market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Eli Lilly's EPS exceed the consensus estimate of $6.84?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What guidance will management provide for future revenue growth?

Management's outlook on revenue growth will be critical for assessing the company's ability to sustain its momentum.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Eli Lilly's recent product launches, which could drive higher-than-expected sales.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

Options are pricing a 6.42% move, but the stock has historically moved more than that, suggesting potential for a larger reaction.

Key Risk

If the company reports strong sales growth in its key therapeutic areas, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

Investors are closely watching how the company balances growth with potential pricing pressures in the pharmaceutical market.

Bull Confirmed If

Eli Lilly must report an EPS above $7.00 and provide strong revenue guidance to confirm the bull case.

Bear Confirmed If

An EPS below $6.50 or weak revenue guidance would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.42%

Historical Avg

±8.6%

Pricing cheap

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±6.4% while LLY has averaged ±8.6% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

20.6%

Calls (2.0M)P/C Ratio: 0.86Puts (1.3M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests a potential stock increase of around +3.13%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around -8.97%, raising concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·5 sells

Members

House + Senate

Est. Notional

$22,008.00–$155,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of diabetes and cancer drugs.
2Any commentary on pricing strategies and market competition.
3Insights into research and development progress for new treatments.
4Management's outlook on global market expansion efforts.
5Details on cost management and operational efficiencies.